Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
264 participants
INTERVENTIONAL
2014-01-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LBR-101 High Dose
Subcutaneous High Dose LBR-101 Administered Monthly x 3
LBR-101 High Dose
Subcutaneously Administered LBR-101 Monthly x 3
LBR-101 Low Dose
Subcutaneous Low Dose LBR-101 Administered Monthly x 3
LBR-101 Low Dose
Subcutaneously Administered LBR-101 Monthly x 3
Placebo
Subcutaneous Placebo Administered Monthly x 3
Placebo
Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LBR-101 High Dose
Subcutaneously Administered LBR-101 Monthly x 3
LBR-101 Low Dose
Subcutaneously Administered LBR-101 Monthly x 3
Placebo
Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study including any known and potential risks and available alternative treatments.
* Chronic migraine meeting the diagnostic criteria listed in the International Classification of Headache Disorders (ICHD-III beta version, 2013)
* Body Mass Index (BMI) of 17.5 to 37.5 kg/m2, and a total body weight between 50 kg and 120 kg inclusive.
* Demonstrated compliance with the electronic headache diary during the run-in period headache data on a minimum of 22/28 days (80% diary compliance)
Exclusion Criteria
* Subject has received onabotulinum toxin A for migraine or for any medical or cosmetic reasons requiring injections in the head, face, or neck during the 6 months prior to study entry.
* Subject is using medications containing opioids (including codeine) or barbiturates (including Fiorinal®, Fioricet®, or any other combination containing butalbital) on more than 4 days per month for the treatment of migraine or for any other reason.
* Failed \> 2 medication categories or \> 3 preventive medications (within two medication categories) due to lack of efficacy for prophylactic treatment of episodic or chronic migraine after an adequate therapeutic trial
* Treatment with an investigational drug or device within 30 days of study entry or any prior exposure to a monoclonal antibody targeting the CGRP pathway.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Teva Medical Expert, MD
Role: STUDY_DIRECTOR
Teva Branded Pharmaceutical Products R&D, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Teva Investigational Site 145
Gilbert, Arizona, United States
Teva Investigational Site 130
Phoenix, Arizona, United States
Teva Investigational Site 117
Scottsdale, Arizona, United States
Teva Investigational Site 161
Anaheim, California, United States
Teva Investigational Site 116
Fullerton, California, United States
Teva Investigational Site 119
Long Beach, California, United States
Teva Investigational Site 146
Oceanside, California, United States
Teva Investigational Site 113
San Francisco, California, United States
Teva Investigational Site 108
Stanford, California, United States
Teva Investigational Site 112
Walnut Creek, California, United States
Teva Investigational Site 132
Boulder, Colorado, United States
Teva Investigational Site 162
Stamford, Connecticut, United States
Teva Investigational Site 143
DeLand, Florida, United States
Teva Investigational Site 137
Hialeah, Florida, United States
Teva Investigational Site 101
Jacksonville, Florida, United States
Teva Investigational Site 166
Jacksonville, Florida, United States
Teva Investigational Site 129
Maitland, Florida, United States
Teva Investigational Site 167
Orlando, Florida, United States
Teva Investigational Site 139
Ormond Beach, Florida, United States
Teva Investigational Site 140
Port Orange, Florida, United States
Teva Investigational Site 149
Atlanta, Georgia, United States
Teva Investigational Site 164
Decatur, Georgia, United States
Teva Investigational Site 134
Douglasville, Georgia, United States
Teva Investigational Site 125
Evansville, Indiana, United States
Teva Investigational Site 133
Lenexa, Kansas, United States
Teva Investigational Site 135
Brockton, Massachusetts, United States
Teva Investigational Site 124
New Bedford, Massachusetts, United States
Teva Investigational Site 151
Springfield, Massachusetts, United States
Teva Investigational Site 109
Watertown, Massachusetts, United States
Teva Investigational Site 115
Worcester, Massachusetts, United States
Teva Investigational Site 110
Ann Arbor, Michigan, United States
Teva Investigational Site 114
Kalamazoo, Michigan, United States
Teva Investigational Site 150
Golden Valley, Minnesota, United States
Teva Investigational Site 152
Kansas City, Missouri, United States
Teva Investigational Site 107
Springfield, Missouri, United States
Teva Investigational Site 104
St Louis, Missouri, United States
Teva Investigational Site 148
Reno, Nevada, United States
Teva Investigational Site 105
The Bronx, New York, United States
Teva Investigational Site 131
Greensboro, North Carolina, United States
Teva Investigational Site 118
Raleigh, North Carolina, United States
Teva Investigational Site 168
Winston-Salem, North Carolina, United States
Teva Investigational Site 122
Canton, Ohio, United States
Teva Investigational Site 141
Cincinnati, Ohio, United States
Teva Investigational Site 142
Cincinnati, Ohio, United States
Teva Investigational Site 155
Cleveland, Ohio, United States
Teva Investigational Site 102
Columbus, Ohio, United States
Teva Investigational Site 127
Oklahoma City, Oklahoma, United States
Teva Investigational Site 111
Philadelphia, Pennsylvania, United States
Teva Investigational Site 120
Goose Creek, South Carolina, United States
Teva Investigational Site 153
Bristol, Tennessee, United States
Teva Investigational Site 126
Memphis, Tennessee, United States
Teva Investigational Site 154
Nashville, Tennessee, United States
Teva Investigational Site 128
Arlington, Texas, United States
Teva Investigational Site 121
Austin, Texas, United States
Teva Investigational Site 136
Austin, Texas, United States
Teva Investigational Site 123
Charlottesville, Virginia, United States
Teva Investigational Site 144
Roanoke, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
VanderPluym J, Dodick DW, Lipton RB, Ma Y, Loupe PS, Bigal ME. Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. Neurology. 2018 Sep 18;91(12):e1152-e1165. doi: 10.1212/01.wnl.0000544321.19316.40. Epub 2018 Aug 17.
Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. Cephalalgia. 2019 Jan;39(1):52-60. doi: 10.1177/0333102418772585. Epub 2018 May 3.
Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines. Headache. 2017 Oct;57(9):1375-1384. doi: 10.1111/head.13156. Epub 2017 Sep 1.
Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov;14(11):1091-100. doi: 10.1016/S1474-4422(15)00245-8. Epub 2015 Sep 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LBR-101-021
Identifier Type: -
Identifier Source: org_study_id